Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new study suggests that common erectile dysfunction drugs may do more than expected. Researchers found that men with type 2 diabetes who took PDE5 inhibitors — like Viagra or Cialis — were significantly less likely to develop proliferative diabetic retinopathy, a severe, vision-threatening condition. The findings open the door to exploring these widely used drugs as a potential protective factor against serious eye disease.
ED drugs and eye protection: an unexpected connection
A large retrospective study published in Eye found that men with both type 2 diabetes and erectile dysfunction who used PDE5 inhibitors (think sildenafil/Viagra, tadalafil/Cialis) had notably lower rates of developing proliferative diabetic retinopathy — the most advanced, sight-threatening form of the disease — compared to non-users over up to 7 years of follow-up.
The study matched 1,823 PDE5 inhibitor users with 1,823 non-users and tracked eye health outcomes. While the overall reduction in diabetic retinopathy risk (17%) didn't hold up after statistical adjustment, the drop in proliferative diabetic retinopathy was striking and remained statistically significant even after corrections.
By the Numbers
Why it matters: Diabetic retinopathy is a leading cause of blindness worldwide, and treatment options remain limited. If PDE5 inhibitors — already widely prescribed — can meaningfully reduce the risk of its most dangerous form, that's a potentially game-changing insight worth investigating further in prospective trials.
